NVAX
A 7.07$ les ha salido la compra a los de Eagle Assets Management, podrían haber comprado mejor, pero es un buen precio.
Edito.- En el tercer trimestre inician su posición con 825.706 accs. a 7.07$. Esta última compra es de 1.651.412 accs, exactamente el doble de lo que ya tenían y al mismo precio. Casualidades, jeje.
Lo que no sabia que Aguila Asset Management, aumento su posición en Portola Pharmaceuticals Inc
http://www.dakotafinancialnews.com/portola-pharmaceuticals-inc-ptla-stake-raised-by-eagle-asset-management/765229/
¿Qué te parece Portola?
$AMRN Week 18/12 –V–
TRx:15,693{vs15,610; +0.53%}Sec +0.51%
NRx:6,835{vs6,737; +1.45%}Sec +0.22%--ATH
Ref:8,858 {vs8,873; -0.14%}Sec +0.71%
V TRx Mkt Share: 17.31% vs 17.31% -- = ATH
V NRx Mkt Share:19.15% vs 18.92% -- ATH
V Ref Mkt Share:16.11% vs 16.25%--(ATH = 16.25)
L:
TRx: 3,962{vs 3,826; +3.55%}
NRx: 1,424{vs 1,309; +8.79%}
GenL:
TRx: 71,010 {vs 70,765; +0.35%}
NRx: 27,428 {vs 27,654; -0.49%}
----------------------------
Short Interest Update: -8.87%
15/12/15: 21,863,261 Change: -2,128,797
30/11/15: 23,992,058
Biotech Is Ready to Resume a Leadership Role
http://www.thestreet.com/story/13407365/1/biotech-is-ready-to-resume-a-leadership-role.html
segun este tipo
resistencia en 342
OCAT
Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells in the journal PLOS One by Ocata and its collaborators at the University of Miami, UCSD, and Stanford University.
Presents a method for generating scalable amounts of human embryonic stem cell derived corneal endothelial cells (hESC-CEC).
We have developed a simple, two-step method for generating amounts of hESC-CECs, in-vitro, which does not rely on donor corneas.” Dr. Lanza added, “The ability to manufacture these cells from a single, replenishable stem cell source may provide a potential solution to the worldwide shortage of transplantable corneal tissue. As we near the completion of our acquisition by Astellas, I am excited about the possibility of moving this early research into pre-clinical studies in the future.
PTLA
No puedo decirte nada sobre ésta, Franz, creo que el único que la ha comentado alguna vez y supongo que la seguirá, es davidgiga.
La carrera que lleva desde que salió a cotizar, está muy bien y estos ...http://openinsider.com/insider/Fullerton-Management-Pte-Ltd/1379348
cargaron 750k cromos a 48$ el 9 de Dicbre.
